High resolution imaging and five-year tuberculosis contact outcomes.


Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
03 Jul 2023
Historique:
pubmed: 18 7 2023
medline: 18 7 2023
entrez: 18 7 2023
Statut: epublish

Résumé

The evolution of tuberculosis (TB) disease during the clinical latency period remains incompletely understood. 250 HIV-uninfected, adult household contacts of rifampicin-resistant TB with a negative symptom screen underwent baseline At baseline, 59 (23.6%) participants had lung PET/CT findings consistent with TB of which 29 (11.6%) were defined as Subclinical TB, and 30 (12%) Subclinical TB-inactive. A further 83 (33.2%) had other lung parenchymal abnormalities and 108 (43.2%) had normal lungs. Over 1107-person years of follow-up 14 cases of culture-positive TB were diagnosed. Six cases were detected by intensive baseline screening, all would have been missed by the South African symptom-based screening strategy and only one detected by a WHO-recommended chest X-Ray screening strategy. Those with baseline Subclinical TB lesions on PET/CT were significantly more likely to be diagnosed with culture-positive TB over the study period, compared to those with normal lung parenchyma (10/29 [34.5%] vs 2/108 [1.9%], Hazard Ratio 22.37 [4.89-102.47, p<0.001]). These findings challenge the latent/active TB paradigm demonstrating that subclinical disease exists up to 4 years prior to microbiological detection and/or symptom onset. There are important implications for screening and management of TB.

Sections du résumé

Background UNASSIGNED
The evolution of tuberculosis (TB) disease during the clinical latency period remains incompletely understood.
Methods UNASSIGNED
250 HIV-uninfected, adult household contacts of rifampicin-resistant TB with a negative symptom screen underwent baseline
Results UNASSIGNED
At baseline, 59 (23.6%) participants had lung PET/CT findings consistent with TB of which 29 (11.6%) were defined as Subclinical TB, and 30 (12%) Subclinical TB-inactive. A further 83 (33.2%) had other lung parenchymal abnormalities and 108 (43.2%) had normal lungs. Over 1107-person years of follow-up 14 cases of culture-positive TB were diagnosed. Six cases were detected by intensive baseline screening, all would have been missed by the South African symptom-based screening strategy and only one detected by a WHO-recommended chest X-Ray screening strategy. Those with baseline Subclinical TB lesions on PET/CT were significantly more likely to be diagnosed with culture-positive TB over the study period, compared to those with normal lung parenchyma (10/29 [34.5%] vs 2/108 [1.9%], Hazard Ratio 22.37 [4.89-102.47, p<0.001]).
Conclusions UNASSIGNED
These findings challenge the latent/active TB paradigm demonstrating that subclinical disease exists up to 4 years prior to microbiological detection and/or symptom onset. There are important implications for screening and management of TB.

Identifiants

pubmed: 37461515
doi: 10.1101/2023.07.03.23292111
pmc: PMC10350144
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : CC2012
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : U19 AI111276
Pays : United States

Auteurs

Hanif Esmail (H)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.
MRC Clinical Trials Unit at University College London, WC1V 6LJ, United Kingdom.
WHO Collaborating Centre for Tuberculosis Research and Innovation, Institute for Global Health, University College London, WC1E 6JB, United Kingdom.

Anna K Coussens (AK)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.
Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia.

Friedrich Thienemann (F)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.
Department of Internal Medicine, University Hospital of Zurich, University of Zurich, Switzerland.

Bianca Sossen (B)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.

Sandra L Mukasa (SL)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.

James Warwick (J)

Division of Nuclear Medicine, Department of Medical Imaging and Clinical Oncology, Stellenbosch University, Cape Town, South Africa.

Rene T Goliath (RT)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.

Nashreen Omar Davies (NO)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.

Emily Douglass (E)

Division of Infectious Diseases, Center for Emerging Pathogens, New Jersey Medical School, Rutgers University, Newark, NJ, USA.

Amanda Jackson (A)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.

Francisco Lakay (F)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.

Elizabeth Streicher (E)

Department of Science and Technology/National Research Foundation Centre of Excellence in Biomedical Tuberculosis Research, South African Medical Research Council for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa.

Jacob E Munro (JE)

Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia.
Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.

Marilou H Barrios (MH)

Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia.
Advanced Genomics Facility, Advanced Technology and Biology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.

Torben Heinsohn (T)

Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.

Liana Macpherson (L)

MRC Clinical Trials Unit at University College London, WC1V 6LJ, United Kingdom.

Dylan Sheerin (D)

Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia.

Saalikha Aziz (S)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.

Keboile Serole (K)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.

Remy Daroowala (R)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.

Arshad Taliep (A)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.

Petri Ahlers (P)

Department of Science and Technology/National Research Foundation Centre of Excellence in Biomedical Tuberculosis Research, South African Medical Research Council for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa.

Stephanus T Malherbe (ST)

Department of Science and Technology/National Research Foundation Centre of Excellence in Biomedical Tuberculosis Research, South African Medical Research Council for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa.

Rory Bowden (R)

Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia.
Advanced Genomics Facility, Advanced Technology and Biology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.

Robin Warren (R)

Department of Science and Technology/National Research Foundation Centre of Excellence in Biomedical Tuberculosis Research, South African Medical Research Council for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa.

Gerhard Walzl (G)

Department of Science and Technology/National Research Foundation Centre of Excellence in Biomedical Tuberculosis Research, South African Medical Research Council for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa.

Laura E Via (LE)

Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Tuberculosis Imaging Program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Melanie Bahlo (M)

Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia.
Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.

Karen R Jacobson (KR)

Section of Infectious Diseases, Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center, Boston, MA, USA.
Department of Epidemiology, Boston University School of Public Health Boston, MA, USA.

C Robert Horsburgh (CR)

Department of Epidemiology, Boston University School of Public Health Boston, MA, USA.

Padmini Salgame (P)

Division of Infectious Diseases, Center for Emerging Pathogens, New Jersey Medical School, Rutgers University, Newark, NJ, USA.

David Alland (D)

Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, USA.

Clifton Earl Barry (CE)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.
Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Tuberculosis Imaging Program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

JoAnne L Flynn (JL)

Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, PA 15261, United States of America.

Jerrold J Ellner (JJ)

Division of Infectious Diseases, Center for Emerging Pathogens, New Jersey Medical School, Rutgers University, Newark, NJ, USA.

Robert J Wilkinson (RJ)

Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa.
The Francis Crick Institute London NW1 1AT, United Kingdom.
Department of Infectious Diseases, Imperial College London W12 0NN, United Kingdom.

Classifications MeSH